Sugi Predict

Sugi Predict / Compounds / SCHEMBL2362473

SCHEMBL2362473

SCHEMBL2362473

CCOC(=O)Cn1cncn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ FAAH O00519 1/20 0.45
▸ MGLL Q99685 1/20 0.45
▸ EGLN3 Q9H6Z9 1/20 0.44
▸ GSK3A P49840 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929803 0.83 EGLN3 (0.59) CYP1A2FAAHMGLLEGLN3MAPT
SCHEMBL21233106 0.81 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19EGLN3
SCHEMBL9826385 0.78 NPSR1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19EGLN3
SCHEMBL20900432 0.78 EGLN3 (0.52) CYP1A2CYP3A4CYP2D6CYP2C19EGLN3
SCHEMBL7681770 0.78 EGLN3 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19FAAH
SCHEMBL10816033 0.77 EGLN3 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19EGLN3
SCHEMBL4291631 0.76 EGLN3 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19EGLN3
SCHEMBL7684254 0.76 EGLN3 (0.46) FAAHMGLLEGLN3MAPTHSP90AA1
SCHEMBL23139055 0.75 NLRP3 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19FAAH
SCHEMBL23118100 0.75 NLRP3 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
WO-2024064778-A2 SMALL MOLECULE INHIBITORS OF NEUTROPHIL EXOCYTOSIS AND INFLAMMATION THE SCRIPPS RESEARCH INSTITUTE (US) 2024-03-28 — — WO disclosed
US-10391082-B2 Protein kinase inhibitors ORION CORPORATION (FI) 2019-08-27 — — US disclosed
US-20180250272-A1 PROTEIN KINASE INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2018-09-06 — — US disclosed
US-20160346254-A1 PROTEIN KINASE INHIBITORS ORION CORP (FI) 2016-12-01 — — US disclosed
US-9447091-B2 Protein kinase inhibitors ORION CORPORATION (FI) 2016-09-20 — — US disclosed
US-20160229858-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-08-11 — — US disclosed
EP-2766354-B1 PROTEIN KINASE INHIBITORS ORION CORP (FI) 2016-05-18 — — EP disclosed
CN-103958500-B Kinases inhibitor ORION CORP. (FI) 2016-04-27 — — CN disclosed
CN-101631785-A Substituted dihydropyrazolones for the treatment of cardiovascular and hematological disorders BAYER SCHERING PHARMA AG 2010-01-20 — — CN disclosed
WO-2009050185-A1 1,3,5-TRISUBSTITUTED TRIAZOLE DERIVATIVE JANSSEN PHARMACEUTICA NV (BE) 2009-04-23 — — WO disclosed
EP-1423363-B1 ORAL ANTIDIABETIC AGENTS WARNER LAMBERT CO (US) 2006-04-19 — — EP disclosed
EP-1577305-A1 Oral antidiabetic agents WARNER-LAMBERT COMPANY LLC (US) 2005-09-21 — — EP disclosed
CN-1558897-A oral antidiabetic agent ����-�����ع�˾ 2004-12-29 — — CN disclosed
US-20030171377-A1 Antidiabetic agents BIGGE CHRISTOPHER FRANKLIN (US) 2003-09-11 — — US disclosed
US-4584008-A FUNGICIDES AND PLANT GROWTH REGULATORS CHEVRON RESEARCH COMPANY (US) 1986-04-22 — — US disclosed
EP-0102163-A1 Triazole derivatives and compositions containing the same CHEVRON RESEARCH COMPANY (US) 1984-03-07 — — EP disclosed
US-4394380-A HERBICIDES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-07-19 — — US disclosed
US-4315016-A FUNGICIDES IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171377-A1 Antidiabetic agents SLC5A1, SLC5A2, GLP1R CYP1A2 971/4885CYP3A4 309/4885CYP2D6 140/4885
US-20160229858-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES THPO, PFKP, DCK CYP1A2 1105/4885CYP3A4 1003/4885CYP2D6 449/4885
US-20160346254-A1 PROTEIN KINASE INHIBITORS FGFR1, FGFR3, FGFR4 CYP1A2 3606/4885CYP3A4 2307/4885CYP2D6 2925/4885
US-20180250272-A1 PROTEIN KINASE INHIBITORS FGFR1, FGFR3, FGFR4 CYP1A2 3587/4885CYP3A4 2241/4885CYP2D6 2927/4885
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF MAT1A, AMD1, MAT2B CYP1A2 465/4885CYP3A4 391/4885CYP2D6 524/4885
US-10391082-B2 Protein kinase inhibitors FGFR1, FGFR3, FGFR4 CYP1A2 3587/4885CYP3A4 2241/4885CYP2D6 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.